Emboline is one step closer to the commercialization of its Emboliner Embolic Protection System. The Santa Cruz, CA-based ...

In the first head-to-head comparison of two devices intended to protect against stroke in patients undergoing transcatheter ...

Emboline, Inc., a privately held medical technology company developing embolic protection solutions for structural heart procedures, today announced positive results from its pivotal PROTECT H2H ...

Older patients with coronary artery disease scheduled for transcatheter aortic valve replacement (TAVR) had comparable ...

Medtronic (NYSE:MDT) today announced data from the ALERT trial aimed at addressing health disparities in structural heart care.

Transcatheter aortic valve replacement with self-expanding valves was associated with significantly lower mean aortic valve ...

The FDA PMA for JenaValve's Trilogy device for TAVR-AR comes months after a court struck down Edwards Lifesciences attempt to ...

Please provide your email address to receive an email when new articles are posted on . At 5 years, there was no difference in death or disabling stroke between transcatheter aortic valve replacement ...

Background Transcatheter aortic valve replacement (TAVR) has already been recommended for some high-risk patients with aortic ...

Given today's short hospital stays after transcatheter aortic valve replacement (TAVR), there may be a role for selective long-term monitoring to flag delayed conduction abnormalities, studies showed.

SAN DIEGO, CA—Complications after TAVR are associated with longer hospital stays, higher costs, and increased resource utilization, but one center’s experience with surgeons at the helm shows that ...

WASHINGTON, DC — Transcatheter aortic valve replacement (TAVR) is superior to surveillance in patients with severe but asymptomatic aortic stenosis with no apparent cost in adverse events, according ...